About this trial
Venous thromboembolic disease (VTE) is a common (1/1000), potentially serious disease (10% mortality when the clinical presentation is that of pulmonary embolism (PE)). In cancer patients, the risk of developing VTE is high and constitutes a negative prognostic factor for cancer; the risk of bleeding is also increased. The study of VTE in the context of cancer is a major challenge, given the frequency of the association, the heterogeneity of the situations, the risk factors involved and the therapeutic issues in both curative and primary prevention; in this field, many uncertainties remain, justifying a study focused on the association of VTE and cancer.
Eligibility criteria
Qualifiers
Patients aged 18 years and more.
Patients with active cancer or requiring cancer treatment at the time of their VTE episode
Patients with documented VTE less than 2 years old
Patients affiliated to the social security system
Disqualifiers
Patient under 18
Refusal to participate
Incapacity to consent to the study
Patient under guardianship
Trial design
Treatments tested in this trial
- Collection of biological samples